XWELL, Inc. (XWEL) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended September 30, 2024. XWELL, Inc. is a global wellness company operating four reportable segments: XpresSpa (airport spa services), XpresTest (bio-surveillance and marketing services), Naples Wax Center (off-airport waxing and skincare), and Treat (airport wellness centers). The company is transitioning from a pandemic-era testing model to a pure-play wellness services strategy, expanding internationally and into off-airport markets.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Total Revenue | $8.42M | $7.47M | $26.43M | $22.71M |
| Gross Profit | $2.05M | $1.09M | $7.80M | $2.80M |
| Operating Loss | $(4.77M) | $(12.09M) | $(9.04M) | $(23.10M) |
| Net Loss (Attributable to XWELL) | $(4.75M) | $(11.53M) | $(9.26M) | $(22.77M) |
| Cash & Cash Equivalents | $4.37M | - | - | - |
| Marketable Securities | $11.66M | - | - | - |
| Working Capital | $9.66M | - | - | - |
| Operating Cash Flow (YTD) | $(7.54M) | $(12.87M) | - | - |
Note: All figures in thousands except per share data. No long-term debt is reported; liabilities consist primarily of operating lease obligations ($11.6M total).
Material Changes vs. Prior Period
- Revenue Growth: Q3 revenue increased 13% year-over-year, driven by the expansion of the XpresTest CDC bio-surveillance contract and the inclusion of Naples Wax Center (acquired Sept 2023).
- Improved Operating Loss: Operating loss narrowed significantly from $12.09M in Q3 2023 to $4.77M in Q3 2024. This improvement is largely due to the absence of massive impairment charges recorded in the prior year ($8.4M in Q3 2023 vs. $0.15M in Q3 2024) and cost optimization.
- Expense Fluctuations: General and administrative expenses increased 51% in Q3 2024 compared to Q3 2023, primarily due to one-time legal fees of approximately $2.1M related to the defense of the CPC lawsuit. Salaries and benefits also rose due to executive severance and the absence of Employee Retention Credits (ERC) that reduced expenses in the prior year.
- Segment Performance: XpresTest turned profitable with an operating income of $1.14M in Q3 2024, compared to a loss of $5.27M in the prior year. XpresSpa remains the largest revenue generator but continues to operate at a loss.
Guidance, Outlook, and Risks
- Liquidity: Management believes current liquidity (approx. $16M in cash and marketable securities) is sufficient to fund operations for the next 12 months. A registered direct offering in August 2024 raised approximately $1.4M.
- Strategic Outlook: The company is focusing on international expansion (Dubai, Abu Dhabi, Amsterdam, Istanbul) and off-airport growth via Naples Wax and the planned "XWELL Studios" in Jacksonville, FL (targeting 2025).
- Legal Contingencies:
- CPC Lawsuit: A lawsuit filed by CPC Pain & Wellness SPV, LLC regarding board nominations was dismissed in August 2024 after the plaintiff agreed to withdraw nominations.
- Philadelphia Lease: A dispute regarding a sublease at Philadelphia International Airport was settled and discontinued in June 2024.
- Settlement Shares: The company issued 416,000 shares of common stock in August 2024 to settle a legal matter.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of September 30, 2024, due to material weaknesses. Remediation efforts include engaging outside service providers for valuation and accounting and upgrading cloud-based accounting systems.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $7.5M operating cash outflow (YTD 2024) against the $16M liquid asset base.
- One-Time Expenses: Confirm the extent to which the Q3 operating loss was impacted by the $2.1M in legal fees and $0.4M in severance to assess normalized operating performance.
- Internal Control Remediation: Monitor progress on the remediation of material weaknesses in internal controls over financial reporting, as noted in Item 4.
- Segment Viability: Assess the long-term profitability of the XpresSpa segment, which continues to generate significant operating losses despite revenue leadership.
- Equity Dilution: Review the impact of recent share issuances (August 2024 offering and legal settlement shares) on per-share value and ownership structure.